PXL 01

Drug Profile

PXL 01

Alternative Names: PXL-01

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaSurgics
  • Class Glycoproteins; Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Post-surgical adhesions

Most Recent Events

  • 17 May 2017 Promore Pharma announces intention to submit Clinical Trial Apllications in Europe for Post-surgical adhesions (Prevention) in late 2017
  • 17 May 2017 Promore Pharma files an IND application with the Drugs Controller General in India for Post-surgical adhesions (Prevention)
  • 30 Sep 2016 Promore Pharma plans a phase III trial for Post-surgical adhesions (Prevention) in Europe (Promore Pharma pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top